Navigation Links
Preclinical Update - Debio-0512 Therapeutic Vaccine for the,Treatment of Chronic and Acute Inflammatory Conditions

Proof of Concept in Mice Transgenic for Human TNFa

LAUSANNE, Switzerland, March 12, 2007 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions, announces the presentation of preclinical results that validate the mechanism of action of Debio-0512 as an anti-TNFa therapeutic vaccine, that inhibits inflammatory processes in animal models of acute and chronic inflammation. Debio-0512 is a keyhole limpet hemocyanin (KLH)-human TNFa heterocomplex (hTNFa kinoid). The results of this study, published recently in the Proceedings of the National Academy of Sciences (PNAS), were presented on March 10 at the 4th International Conference on Tumor Microenvironment in Florence, Italy.

"These results confirm that therapeutic vaccination against human TNFa could represent in the future, an effective approach for the treatment of TNFa-dependent inflammatory pathologies including rheumatoid arthritis and Crohn's disease," said Professor Daniel Zagury of the University Pierre et Marie Curie (Paris) and co-author of the report. "Debiopharm's plan is for IND enabling clinical studies to be ready by the end of this year. We believe that active immunization may offer advantages over passive anti-TNFa monoclonal antibody therapy, by potentially limiting therapeutic failure related to the formation of anti-idiotypic antibodies. Moreover, the potential low frequency of boost immunizations would increase patient compliance."

TNFa is a well-established pro-inflammatory mediator. In hTNFa expressing transgenic mice (TTg mice), a mouse model of rheumatoid arthritis, animals receiving the Debio-0512 therapeutic vaccine developed high levels of anti-TNFa antibodies, neutralising both TNFa bioactivity and binding of TNFa to its receptor. This study shows that immunization with Debio-0512 effectively controls pathogenic effec ts triggered by TNFa in this mouse model of rheumatoid arthritis.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development company that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.6 billion in 2006.

For more information on Debiopharm Group, please visit: www.debiopharm.com.

CONTACT: Debiopharm S.A. Contacts: Herve Porchet, VP, Medical Affairs,Tel.: +41-21-321-01-11, Fax: +41-21-321-01-69, . KimBill, VP, Business & Legal Affairs, . Additional MediaContacts: In London: Maitland, Brian Hudspith, Tel: +44-(0)20-7379-5151,. In New York: Noonan Russo, Wendy Lau, Tel:+1-212-845-4272, Fax: +1-212-845-4260, hporchet@debio.com kbill@debio.com bhudspith@maitland.co.uk wendy.lau1@eurorscg.com

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
3. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
4. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
5. ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model
6. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
7. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
8. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
9. Genaera to Present Preclinical Data on Trodusquemine for the Treatment of Obesity at the American Diabetes Association 67th Scientific Sessions
10. Metabasis Therapeutics Presents Results of Preclinical Studies for MB07811, Its Novel Product Candidate for the Treatment of Hyperlipidemia, at the Endocrine Societys Annual Meeting
11. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/31/2016)... May 31, 2016 Aloe vera ... food, cosmetics and pharmaceuticals, with global volume to surpass ... 1.6 Bn. Demand for aloe vera extracts ... yogurts will continue its upward momentum in 2016 as ... boost positive sentiment on aloe vera, with wide-ranging applications ...
(Date:5/31/2016)... , May 31, 2016 The global ... coupled with surging prevalence of deaths from chronic diseases. According ... By Region, By Country): Opportunities and Forecasts (2016-2021) - (By ... Orthopaedic, Cardiovascular, Plastic Surgery, Wound Care); By Region-North America, ... UK, Germany , Italy ...
(Date:5/31/2016)... May 31, 2016 , Isansys  Lifecare, ... its Patient Status Engine wireless patient monitoring platform, as it ... Germany , Scotland and ... 2 nd generation system, launched earlier this year, is now ... , , This new technology significantly enhances ...
Breaking Medicine Technology:
(Date:5/31/2016)... ... ... A book about the self-discovery of one’s limitless creative power, “ Unleash Your ... give readers the courage they need to embrace their creativity and unleash it as ... my life to learn and create what I set my heart with no limits ...
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... "ProDrop 3D ... projects to the next level," said Christina Austin - CEO of Pixel Film Studios. ... Studios. With ProDrop 3D Abstract have the ability to generate and manipulate three-dimensional shapes ...
(Date:5/31/2016)... ... ... According to recent statistics, there are nearly half a million physical therapists ... physical therapy professional and every clinic has a duty to perform at the highest ... competitive industry is also essential. The solution that many physical therapy leaders turn to ...
(Date:5/31/2016)... (PRWEB) , ... June 01, 2016 , ... ... “ Psoriasis and smoking: links and risks ”. , As corresponding author Professor ... on the relation between smoking habits and psoriasis. Smoking influences the onset and ...
(Date:5/31/2016)... ... May 31, 2016 , ... ... that considers individuals’ genetic characteristics and the physical and behavioral worlds in ... in sync. In personalized medicine, diagnosing an individual’s disease depends on accurately ...
Breaking Medicine News(10 mins):